ClinicalTrials.gg
RecruitingNCT07591519Updated Jul 16, 2026

Clinical Trials of IBI3035 in Healthy Subjects

A Phase 1 interventional study of IBI3035 and Insulin icodec Injection in Healthy Person, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This study is a Phase I clinical trial that uses positive glucose clamping technology to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence of IBI3035 with insulin injection (Awiqli?) after a single administration in healthy male subjects

02

Conditions studied

  • Healthy Person
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The following inclusion criteria must be met:

  1. Healthy male adult subjects aged 18 to 45 years (including 18 and 45 years, based on the date of signing the form) of Chinese nationality;
  2. (BMI) between 19.0 and 24.0 kg/m2 (including both values) at screening, and weight ≥ 50 kg;
  3. Normal glucose tolerance at screening [3.9 mmol/L \< fasting blood glucose \< 6.1 mmol/L, and 2-hour post-glucose load blood glucose \< 7.8 mmol/L in the oral glucose tolerance test (OGTT)]; normal insulin secretion function or abnormality without clinical significance as determined by the investigator [confirmed by the insulin release test (IRT)];
  4. ≤ 6.0% at screening;
  5. Agree to take effective measures during the study period and within 6 months after the last dose and have no plan to donate sperm;
  6. Able to understand the procedures and methods of this study, willing to strictly follow the clinical trial protocol to complete the trial, and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion Criteria

Subjects who meet any of the following exclusion criteria cannot be included in this study:

  1. Known or suspected to be allergic to the drug in this study;
  2. Have taken any drugs that affect insulin hypoglycemic effects within 28 days before screening (such as , diuretics, epinephrine, salbutamol, glucagon, thyroid hormones, etc.);
  3. Have a history of clinical significance as determined by the investigator at screening or before randomization, including diseases of the endocrine system, blood system, cardiovascular system, respiratory system, digestive system, urinary system, immune system, nervous system, or any other disease that can significantly alter the absorption, metabolism, or elimination of drugs;
  4. Have a clear diagnosis of hyperglycemia or hypoglycemia within 3 months before screening;
  5. Have an increased risk of thrombosis at screening, including personal or family history of deep vein thrombosis;
  6. Have abnormal indicators with clinical significance at screening or before randomization: vital signs, physical examination, laboratory tests, chest X-ray, and 12-lead as determined by the investigator;
  7. Have had a severe infection, trauma, or surgery within 4 weeks before screening;
  8. Have smoked more than 5 cigarettes per day within 3 months before screening, or have smoked within 48 hours before using the investigational drug or cannot stop using any tobacco products during the trial;
  9. Have used any prescription drugs, Chinese herbal medicines, over-the-counter drugs, or health supplements (except for regular vitamin supplements) within 2 weeks before screening;
  10. Have donated blood ≥ 400 ml or had any component blood donation within 3 months before screening, or have lost a total of ≥ 400 ml of blood for any reason, or have a history of blood transfusion or use of blood products;
  11. Have consumed more than 14 units of alcohol per week within 3 months before screening: 1 unit ≈ 360 ml of beer, or 45 ml of spirits, or 150 ml of wine, and cannot abstain from alcohol within 48 hours before using the investigational drug;
  12. Have consumed excessive amounts of tea, coffee, and/or caffeine-rich beverages (more than 8 cups, 1 cup ≈ 250 ml) daily within 3 months before screening;
  13. Have positive results for (HIV) antibodies, surface antigen (HBsAg), virus (HCV) antibodies, or Treponema pallidum antibodies;
  14. Have a history of drug abuse or drug use within 3 months before screening, or have positive results for alcohol tests or urine drug screening at screening. 15. Participants who have participated in other clinical trials and used investigational drugs or medical devices within the 3 months prior to screening;

16. Participants with a weight change greater than 5% within the 3 months prior to screening [(maximum weight within the 3 months prior to screening - minimum weight within the 3 months prior to screening) / minimum weight within the 3 months prior to screening × 100%, as self-reported by the participant]; 17. Participants with any food allergies or special dietary requirements that prevent them from adhering to a uniform diet (such as intolerance to standard meal foods, lactose intolerance, etc.); 18. Participants who have experienced acute diseases during the screening period; 19. Participants with a history of fainting at the sight of needles or blood, who cannot tolerate venipuncture blood collection, or who have difficulty with blood collection; 20. Participants for whom the investigator deems there to be any circumstances that make them unsuitable for participation in the trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Active comparator
    Insulin icodec Injection

    The first cycle is Awiqli® 1 U/kg, and the second cycle is IBI3035 1 U/kg

    Biological: IBI3035 · Biological: Insulin icodec Injection

  • Experimental
    IBI3035

    The first cycle is IBI3035 1 U/kg, and the second cycle is Awiqli® 1 U/kg

    Biological: IBI3035 · Biological: Insulin icodec Injection

Interventions

  • BiologicalIBI3035

    IBI3035 administered subcutaneously(SC)

  • BiologicalInsulin icodecStudies of Insulin icodecInsulin icodec pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Insulin icodec Injection administered subcutaneously(SC)

06

What researchers measure

Primary outcomes

  1. The area under the blood drug concentration-time curve from 0 to 168 hours

    Time frame: From 0 to 168 hours after administration

  2. Area Under Curve Glucose Infusion Rate (AUCGIR) 0-168h

    Time frame: From 0 to 168 hours after administration

Secondary outcomes

  1. Area Under Curve (AUC0-84h)

    Time frame: From 0 to 84 hours after administration

  2. Tmax

    Time frame: From 0 to 168 hours after administration

  3. Glucose Infusion Rate (GIR) max

    Time frame: From 0 to 168 hours after administration

  4. Area Under Curve Glucose Infusion Rate (AUCGIR) 24-48h

    Time frame: From 24 to 48 hours after administration

  5. Adverse events (AE)

    Time frame: through study completion, an average of 16 weeks

  6. The generation of Anti-drug antibodies (ADA) and Neutrolizing antibodies (NAb if required)

    Time frame: through study completion, an average of 16 weeks

  7. Area Under Curve (AUC) 84-168h

    Time frame: From 84 to 168 hours after administration

  8. Cmax

    Time frame: From 0 to 168 hours after administration

  9. T1/2

    Time frame: From 0 to 168 hours after administration

  10. tGIRmax

    Time frame: From 0 to 168 hours after administration

  11. AUCGIR 144-168h

    Time frame: From 144 to 168 hours after administration

  12. vital signs (Body temperature)

    Time frame: through study completion, an average of 16 weeks

  13. laboratory tests (fasting plasma glucose (GLU))

    Time frame: through study completion, an average of 16 weeks

  14. 12-lead Electrocardiogram (RR interval, PR interval, heart rate (HR), QRS interval, QT interval, QTcF (QTcF = QT/RR^0.33))

    Time frame: through study completion, an average of 16 weeks

  15. vital signs (pulse)

    Time frame: through study completion, an average of 16 weeks

  16. vital signs (respiratory rate)

    Time frame: through study completion, an average of 16 weeks

  17. vital signs (blood pressure: systolic, diastolic)

    Time frame: through study completion, an average of 16 weeks

07

Study locations

1 of 1 sites recruiting
  • Bishan Hospital of Chongqing
    Chongqing, Chongqing Municipality 402760, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Jul 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 15, 2026
StartActual
May 8, 2026
Primary completionEst.
Jul 30, 2027
CompletionEst.
Aug 31, 2027
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07591519
Responsible party
Sponsor
First posted
May 15, 2026
Start date
May 8, 2026
Primary completion
Jul 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jul 16, 2026

Study contacts

Shanyu Xu
Contact
shanyu.xu@innoventbio.com
+86-0512-69566088

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion